|Bid||0.00 x 3100|
|Ask||0.00 x 1400|
|Day's range||76.14 - 77.26|
|52-week range||68.44 - 83.78|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||34.69|
|Earnings date||28 Oct 2021|
|Forward dividend & yield||2.60 (3.38%)|
|Ex-dividend date||14 Sept 2021|
|1y target est||93.02|
Dr. Susannah Hills, Pediatric Airway Surgeon and Assistant Professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Merck (NYSE: MRK) recently won U.S. Food and Drug Administration approval for its pneumococcal vaccine. Pfizer (NYSE: PFE) currently dominates the pneumococcal vaccine market, with its Prevenar 13 generating nearly $6 billion in sales last year. In this Motley Fool Live video recorded on July 21, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss whether or not Merck can beat Pfizer in this multibillion-dollar vaccine market.
Dr. Michael Gonzalez, Emergency Medicine Physician & Assistant Professor at Baylor College of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.